IBM touts quantum-AI convergence and unveils protein simulation breakthrough
Updated
Updated · Constellation Research · May 4
IBM touts quantum-AI convergence and unveils protein simulation breakthrough
11 articles · Updated · Constellation Research · May 4
At Think 2026, Arvind Krishna said quantum advantage could arrive this year as IBM, Cleveland Clinic and RIKEN simulated a 12,635-atom protein complex using Heron processors and Japanese supercomputers.
IBM said the hybrid quantum-classical framework could accelerate drug discovery, while Boeing, Allstate and TCS highlighted uses in materials research, finance, insurance and operations.
Krishna urged companies to build quantum strategies now, alongside post-quantum cryptography plans, as IBM pointed to its 80-plus deployed quantum systems and the 2023 Cleveland Clinic installation.
As supercomputers get faster, could this quantum hybrid approach become obsolete before it is even fully realized?
With a new simulation record set, how long until a quantum computer actually designs a novel, life-saving drug?
Will quantum computers discover new drugs, or will they just create the data to train a more powerful AI?
2026 Breakthrough: Fugaku and IBM Heron Achieve Largest Quantum-Classical Molecular Simulation
Overview
In early 2026, RIKEN and IBM integrated the Fugaku supercomputer with the IBM Quantum Heron processor, enabling a closed-loop hybrid workflow that dynamically exchanged data and orchestrated tasks. This setup powered the largest and most accurate quantum chemistry simulation to date, calculating the electronic structure of iron-sulfur molecules using sample-based quantum diagonalization. The quantum processor sampled complex electron configurations, guiding Fugaku’s classical nodes to focus computational effort, creating a feedback loop that greatly improved accuracy. This milestone demonstrated practical quantum-classical synergy and set new benchmarks. Looking ahead, integrating GPUs is planned to accelerate workflows and bring quantum advantage within reach, with pilot adoption in pharmaceutical research expected by 2028–2030.